NASDAQ:MNKDMannKind Stock Price, Forecast & News

MannKind's stock was trading at $1.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MNKD stock has increased by 51.8% and is now trading at $1.67. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MannKind.

MannKind is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for MannKind.

MannKind Co. (NASDAQ:MNKD) posted its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. The biopharmaceutical company had revenue of $16.24 million for the quarter, compared to analysts' expectations of $15.15 million. View MannKind's earnings history.

5 analysts have issued 1 year price objectives for MannKind's stock. Their forecasts range from $2.50 to $4.00. On average, they expect MannKind's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 79.6% from the stock's current price. View analysts' price targets for MannKind.

Headlines about MNKD stock have been trending positive on Thursday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. MannKind earned a news impact score of 2.1 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news about MannKind.

Some companies that are related to MannKind include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHK), Gilead Sciences (GILD), Micron Technology (MU), Geron (GERN), NVIDIA (NVDA) and Intel (INTC).

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MNKD stock can currently be purchased for approximately $1.67.

MannKind has a market capitalization of $355.94 million and generates $63.04 million in revenue each year. The biopharmaceutical company earns $-51,900,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. MannKind employs 225 workers across the globe.

The official website for MannKind is www.mannkindcorp.com.

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]